Conditions

This is the fourth drug to treat diabetes that also can reduce the risk of heart disease.

A secondary analysis of the TECOS trial affirms sitagliptin does not increase heart failure risk for patients with type 2 diabetes.

According to a new study, one more disease is associated with diabetes: twin study suggests genetic link between obesity, psoriasis and diabetes.

Study shows effect low levels of the hormone have on blood glucose.

Insulin may not be the culprit in poorer outcomes, according to TUXEDO sub-study.

In this week's Homerun Slides, the use of genotyping in understanding the mechanisms of diabetes.

For patients in the U.S., the price of this lifesaving treatment has risen dramatically.

Researchers saw long-term reduction in end-stage renal disease, without evidence of increased risk for cardiovascular events or death.

According to a new study, people with diabetes have a slightly shorter life expectancy than people without diabetes, and many of those years will be marred by disability.

First-time data for the investigational oral formulation of Novo Nordisk's semaglutide were presented at the annual meeting of the Endocrine Society. Billed as one of the company’s brightest pipeline prospects, it has sailed through a phase II trial.